MedTrace Logo

Homoharringtonine Plus Androgen Deprivation Therapy in the Neoadjuvant Treatment of Prostate Cancer: A Single-Arm Clinical Study

NCT07163910 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 93

Last updated 2025-11-18

No results posted yet for this study

Summary

The project aims to verify the therapeutic effect of neoadjuvant homoharringtonine combined with androgen deprivation therapy in patients with localized high-risk/very high-risk, regional lymph node-metastatic, or metastatic prostate cancer before radical prostatectomy through clinical trials, thereby identifying an effective treatment for patients with advanced prostate cancer.

Conditions

Interventions

DRUG

homoharringtonine

Intravenous infusion of 1mg homoharringtonine plus 250ml of 5% glucose injection, administered once daily for two consecutive days.

PROCEDURE

Radical prostatectomy

All patients will undergo radical prostatectomy within 3 weeks (±7 days) after the completion of treatment.

Sponsors & Collaborators

  • The Affiliated Tumor Hospital of Nantong University, Nantong, Jiangsu Province, China

    collaborator OTHER

  • Subei People's Hospital of Jiangsu Province

    collaborator OTHER

  • The First People Hospital of Nantong City

    collaborator UNKNOWN

  • baotai Liang

    lead OTHER

Principal Investigators

  • Chief Physician · Vice President of Zhongda Hospital Affiliated to Southeast University

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-04-20
Primary Completion
2027-09-20
Completion
2027-12-20

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07163910 on ClinicalTrials.gov